The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.50
Bid: 21.00
Ask: 22.00
Change: -2.50 (-10.64%)
Spread: 1.00 (4.762%)
Open: 24.25
High: 21.00
Low: 21.00
Prev. Close: 23.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

Thu, 04th Jan 2024 16:54

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

The FTSE 100 index closed up 40.74 points, 0.5%, at 7,723.07. The FTSE 250 ended up 45.65 points, 0.2%, at 19,372.05, and the AIM All-Share closed up 1.79 points, or 0.2%, at 755.94.

The Cboe UK 100 ended up 0.6% at 771.71, the Cboe UK 250 closed up 0.6% at 16,874.97, and the Cboe Small Companies ended up 0.5% at 14,940.05.

Stocks in New York were higher at the London equities close, with the DJIA up 0.7%, the S&P 500 index up 0.4%, and the Nasdaq Composite up 0.2%.

Since the new year, eyes have been on the US economy and where interest rates may go in 2024.

On Wednesday evening, investors had the minutes from the latest US Federal Reserve meeting, back in December.

At the December meeting, the rate-setting Federal Open Market Committee agreed to hold its benchmark rate steady in a range between 5.25% and 5.5%. Members indicated that they expect three quarter-percentage point cuts by the end of 2024.

"In discussing the policy outlook, participants viewed the policy rate as likely at or near its peak for this tightening cycle, though they noted that the actual policy path will depend on how the economy evolves," the highly anticipated minutes stated.

Officials "reaffirmed that it would be appropriate for policy to remain at a restrictive stance for some time until inflation was clearly moving down sustainably."

On Thursday, focus has been on the health of the US labour market.

The US labour market added more jobs than expected in December, according to a tracker from payroll processing firm ADP.

ADP said sector employment increased by 164,000 jobs in December, picking up from a 101,000 rise in November and ahead of the FXStreet cited consensus of 115,000. The November total of jobs added was revised from 103,000 to 101,000.

Meanwhile, US new jobless claims fell by more than expected in the most recent week.

According to the US Department of Labor, new jobless claims totalled 202,000 in the week ended December 30. This is down from last week's revised level of 220,000. The latest reading came in lower than FXStreet-cited consensus of 216,000.

The data is out ahead of the US nonfarm payrolls Friday.

Meanwhile, in European equities on Thursday, the CAC 40 in Paris and the DAX 40 in Frankfurt both ended up 0.5%.

According to Destatis, Germany's annual inflation picked up to 3.7%, from 3.2% in November. This came in slightly behind FXStreet market consensus of 3.8%.

Capital Economics' Andrew Kenningham commented: "The jump in Germany's headline inflation rate in December came as no surprise as it was driven by energy price subsidies introduced more than a year ago. With core inflation continuing to trend down, it should not affect investors' expectations for the [European Central Bank] to begin cutting interest rates in the coming months."

The pound was quoted at USD1.2696 at the London equities close Thursday, up compared to USD1.2646 at the close on Wednesday. The euro stood at USD1.0961 at the European equities close Thursday, higher against USD1.0915 at the same time on Wednesday. Against the yen, the dollar was trading at JPY144.48, up compared to JPY143.50 late Wednesday.

In the FTSE 100, retailers Next and JD Sports were the best and worst performing blue-chip stocks respectively, after both provided trading updates including the Christmas period.

JD Sports Fashion plummeted 23%, after cutting its profit outlook amid weaker-than-expected sales growth and gross margins.

The retailer said organic revenue was up 6.0% in the 22 weeks that ended December 30 on a constant currency basis from a year earlier, with like-for-like growth of 1.8%. This was slightly behind its expectations. The retailer expects organic revenue growth of around 8% for the year ending February 3.

As a result, it expects to report pretax profit and adjusted items of between GBP915 million and GBP935 million for the financial year. This falls short of market expectations of GBP1.04 billion, which back in September, JD Sports had said it expected to meet.

Next rose 5.5%, on the back of its trading update.

"Clothing retailer Next has set the bar high for the rest of the retail sector by posting a strong trading update this morning," Edison analyst Russell Pointon commented.

In the nine weeks to December 30, the clothing and homewares seller's full price sales were 5.7% higher year-on-year, some GBP38 million better than its previous guidance. It had expected growth of 2.0% year-on-year. The period forms part of its fourth quarter, which concludes on January 27.

The company now expects pretax profit for financial 2024 of GBP905 million, a lift of GBP20 million from its previous outlook, and it would represent a year-on-year increase of 4.0%. Next had initially expected pretax profit of GBP795 million, but it has, now on a number of occasions, lifted its bottom line outlook.

Meanwhile, BP and Shell rose 0.5% and 0.2%, respectively, as oil prices extended their recent upward movements on concerns over the Middle East.

"The region remains a tinder box due to the Israel-Gaza war, and disruption to shipping routes through the Red Sea is also a key factor behind the surge in crude," AJ Bell's investment director Russ Mould explained.

Brent oil was quoted at USD76.60 a barrel at the London equities close Thursday, down from USD78.13 late Wednesday. Over the last week the price has hit highs of USD79.83.

On London's AIM, Angle shares more than doubled to 31.40 pence.

The Surrey-based medical diagnostics provider celebrated "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Gold was quoted at USD2,0445.01 an ounce at the London equities close Thursday, up against USD2,038.89 at the close on Wednesday.

In Friday's UK corporate calendar, MTI Wireless Edge will hold its extraordinary general meeting regarding proposed grant of options to the directors.

The economic calendar for Friday has eurozone inflation readings at 1000 GMT. Before that, there is the UK Halifax house price index at 0700 GMT.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
14 Aug 2020 12:41

Angle's Parsortix Able To Predict Patients' Response To Treatment

Angle's Parsortix Able To Predict Patients' Response To Treatment

Read more
20 Jul 2020 20:03

IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix

IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix

Read more
20 Jul 2020 10:16

Angle's 'Parsortix' advantageous in breast cancer in new research

(Sharecast News) - Angle announced on Monday that the University of Southern California (USC) has published peer-reviewed results of new work undertaken in metastatic breast cancer (MBC), highlighting advantages of a 'Parsortix' liquid biopsy, compared to standard-of-care tissue biopsy.

Read more
25 Jun 2020 12:22

Angle Progresses On Parsortix And De Novo Clearance From US Regulator

Angle Progresses On Parsortix And De Novo Clearance From US Regulator

Read more
18 Jun 2020 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
10 Jun 2020 16:41

IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board

IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board

Read more
12 May 2020 18:54

Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects

Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects

Read more
12 May 2020 08:58

Angle upbeat on recent research using 'Parsortix'

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the liquid biopsy analysis unit at the Health Research Institute of Santiago in Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer, on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs).

Read more
28 Apr 2020 12:28

UK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE

UK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE

Read more
28 Apr 2020 10:03

Angle works with skeleton R&D crew during lockdown

(Sharecast News) - Biopharmaceuticals group Angle said on Tuesday that progress had been impeded by the Covid-19 outbreak as the firm worked with a research and development skeleton crew in Guildford.

Read more
31 Mar 2020 12:21

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

Read more
31 Mar 2020 09:40

Angle UK, US, Canada operations 'severely disrupted' by Covid-19

(Sharecast News) - Liquid biopsy company Angle said on Tuesday that operations in the UK, US and Canada had all been "severely disrupted" by the Covid-19 pandemic.

Read more
3 Mar 2020 18:58

Angle Parsortix Test Used To Help Discover Brain Metastasis

Angle Parsortix Test Used To Help Discover Brain Metastasis

Read more
27 Feb 2020 14:09

Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients

Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients

Read more
27 Feb 2020 12:42

Angle upbeat on recent Parsortix research out of Italy

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that Istituto Nazionale Tumori di Milano in Milan, Italy, has published results of work assessing the performance of its 'Parsortix' system in renal cell carcinoma (RCC), demonstrating key advantages of Parsortix.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.